Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. The company has no approved products for sale and relies on collaboration agreements (notably with sanofi-aventis and Novartis) and contract manufacturing (with Merck) for revenue. The company has incurred cumulative losses of $494.0 million since inception.
Key Financial Metrics
| Metric (in thousands) | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenues | $16,209 | $61,990 |
| Net Income (Loss) | $(4,123) | $64,532 |
| Net Income (Loss) Per Share (Basic) | $(0.07) | $1.17 |
| Operating Cash Flow | $33,132 | $(18,582) |
| Cash and Cash Equivalents (Ending) | $147,816 | $156,227 |
| Total Assets | $470,292 | $506,178 |
| Total Liabilities | $284,508 | $290,565 |
| Convertible Notes Payable | $200,000 | $200,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 74% to $16.2 million from $62.0 million. This was primarily due to the cessation of revenue from the Novartis collaboration (IL-1 Trap) and lower reimbursement from sanofi-aventis for VEGF Trap development expenses.
- Net Loss vs. Profit: The company reported a net loss of $4.1 million compared to net income of $64.5 million in the prior year. The prior year's income was significantly boosted by a $42.75 million "other contract income" payment from Novartis and a $17.8 million loan forgiveness, neither of which occurred in Q1 2005.
- Accounting Change: Effective January 1, 2005, the company adopted SFAS No. 123, recognizing stock-based compensation expense. This resulted in $5.4 million of non-cash expense in Q1 2005, which was not reflected in Q1 2004 operating expenses.
- Collaboration Amendment: In January 2005, Regeneron and sanofi-aventis amended their agreement. Regeneron regained exclusive rights to develop VEGF Trap for eye diseases via local delivery, receiving a one-time $25.0 million payment recognized as "other contract income."
Guidance, Outlook, and Risks
- Outlook: Management expects to incur substantial losses over the next several years as it advances clinical trials for VEGF Trap, IL-1 Trap, and IL-4/13 Trap. The company believes existing capital resources will meet operating needs through at least mid-2007.
- Capital Needs: The company anticipates capital expenditures of $7 million to $9 million for the remainder of 2005. It has filed a shelf registration statement to sell up to $200 million in equity or debt securities but noted no assurance of completion.
- Key Risks:
- Development Uncertainty: Clinical trials for VEGF Trap (cancer and eye diseases) and IL-1 Trap (rheumatoid arthritis) are ongoing with no guarantee of success or regulatory approval.
- Dependence on Partners: Significant reliance on sanofi-aventis for VEGF Trap funding and commercialization, and Merck for contract manufacturing revenue (agreement expires 2006).
- Legal Proceedings: A securities class action lawsuit regarding the safety and efficacy of AXOKINE remains pending; the court denied the company's motion to dismiss in February 2005.
- Competition: Intense competition in oncology (e.g., Genentech's Avastin) and eye disease markets.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for expiration of the Merck manufacturing agreement (2006) and Procter & Gamble/Serono agreements (2005) and the impact on future cash flow.
- Cash Burn Rate: Confirm the company's ability to fund operations through mid-2007 without additional financing, given the shift from large milestone payments to ongoing R&D expenses.
- Stock-Based Compensation Impact: Assess the full-year impact of the new SFAS No. 123 accounting standard on reported net income and operating margins.
- Clinical Trial Progress: Monitor upcoming Phase 1 and Phase 2 results for VEGF Trap (cancer and eye) and IL-1 Trap (rheumatoid arthritis) as these are critical for future valuation.
- Legal Exposure: Track the status of the AXOKINE securities class action lawsuit and potential settlement costs.